NICE Technology Appraisal Guidance No 64, on the use of human growth hormone (somatropin) for the treatment of growth hormone deficiency in adults.

Following consultation, the majority of comments received have led to the decision to defer the review of the existing guidance on the use of human growth hormone (somatropin) for the treatment of growth hormone deficiency in adults until early 2009, when the evidence base will again be assessed to ascertain the need for a review of the guidance.

19 September 2006